VivaVision Announces That VVN539 Has Been Formally Submitted for U.S. Phase II Clinical Trial Application

News

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2022-05-07

Source: Viva Biotech

[Abstract]:VVN539 is the next clinical stage project of VivaVision after VVN001, which is expected to become a competitive ophthalmic drug globally.

VivaVision, an innovative ophthalmic drug company which invested and incubated by Viva BioInnovator, announced that it has submitted a Phase II clinical trial application for the new drug VVN539 for the treatment of open-angle glaucoma to the FDA on May 5, 2022, and will start the clinical study in June 2022.

VVN539 is a new generation, dual-targeted IOP-lowering drug that acts on the trabecular meshwork of the eye to increase the outflow of aqueous humor, thereby reducing IOP. In preclinical animal models, VVN539 has shown excellent IOP-lowering efficacy.

Previous Page：AIxplorerBio Entered A Broad Collaboration with Baidu’s PaddleHelix to Expedite the Construction of Its AI Small Molecule Drug R＆D Platform Next Page：Portfolio Highlights: Clinical and Financing Updates of QurAlis, Apeiron and QureBio

Back

Media contact: vivapr@vivabiotech.com